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Background: Right Ventricular failure is a serious condition associated with high mortality. Temporary mechanical right ventricular support could 
be a reasonable alternative option to save patients life when adjunctive and pharmacologic therapies failed to restore the hemdoynamics. We report 
here the initial first clinical evaluation of a novel minimally invasive percutaneous right ventricular assist device.
Methods: Impella RP is a new, minimally invasive, 3D catheter-based percutaneous microaxial pump that is designed for short-term right 
ventricular support. The device requires single vascular access through a sheath in the femoral vein. The device (22 Fr pump mounted on an 11 
Fr catheter) is positioned under fluoroscopic guidance using a 0.025” wire. It aspirates blood from the inferior vena cava and expels it into the 
pulmonary artery at the maximum rate of up to 4.4 liters per minute. The device requires low anticoagulation regimen.
Results: A First in Man pre-market clinical feasibility evaluation has been initiated at several sites in Canada and Europe in patients experiencing 
right ventricular failure in different clinical settings. At the time of the submission of this abstract a series of patients have been enrolled. Indications 
for use included right ventricular failure post heart transplant, right ventricular failure post cardiac surgery and right ventricular failure post left VAD 
implantation. The implant of the device was feasible and successful in 100% of the patients. The support time ranged from 1 to 7 days, with more 
than 60% of the patients being supported for longer than 4 days. The average flow was 3.6-3.8 L/min. There was no major device-related morbidity. 
The clinical evaluation is ongoing and we plan to present the data on the full cohort at the meeting.
Conclusions: A novel percutaneous right ventricular assist device has been developed. The preliminary clinical experience is very encouraging. The 
results of this First-in-Man clinical experience with the Impella RP will be presented at the meeting.
